ClinicalTrials.gg
CompletedNCT07945392Updated Nov 18, 2026

Preliminary Exploration of the Influence of Alcohol Consumption Levels on the Plasma Cell-free DNA Methylation Profiles in Subjects With Chronic Hepatitis B

An observational study in CHB, sponsored by Beijing Municipal Administration of Hospitals. Completed at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Beijing Municipal Administration of Hospitals · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
99
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 377 studies in Hepatitis B, Chronic with a site in China — 90 open to participants now, 111 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
92nd of 100
99 · median 500
Started
2025
with 23 others
Observational
100 of 377
34 open now
Registered
375th of 377
by date

Among the 377 studies in Hepatitis B, Chronic with a site in China, this one is the 92nd largest by enrollment of the 100 observational ones that give a count, is one of 24 that started in 2025, is one of 100 observational ones, and was the 375th registered.

Hepatitis B, Chronic

898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

90 of the 377 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Existing studies have confirmed that there are differences in the methylation status of liver tissue due to hepatitis B virus infection and alcohol consumption. There are also differences in the methylation status at each stage of the disease progression from hepatitis to liver cirrhosis and then to liver cancer. However, no study has systematically compared the cfDNA methylation profiles of hepatitis B subjects under different alcohol consumption statuses. Plasma cfDNA methylation detection has been proven to be applicable for the early warning of HBV - related liver cancer and has the characteristics of being non - invasive and allowing dynamic monitoring. However, most of the existing markers focus on the "liver cancer transformation" stage, and there is a lack of typing markers suitable for the early stage of "hepatitis progression". To preliminarily explore this field, this project was initiated.

This study is an observational and exploratory study that does not involve clinical treatment intervention for the subjects. The project plans to enroll 85 subjects with chronic hepatitis B. They will be divided into a non - drinking group, a drinking group, and a group that has developed alcoholic hepatitis due to alcohol consumption according to the degree of alcohol consumption. For each patient, 2 tubes of peripheral blood (about 8 mL per tube), a total of about 16 mL, will be collected for cfDNA methylation analysis. By comparing the plasma cfDNA methylation profiles of chronic hepatitis B subjects with different degrees of alcohol consumption, the impact of different degrees of alcohol consumption on the cfDNA methylation of the subjects will be analyzed.

Read the detailed description

The study subjects were all inpatients and outpatients with chronic hepatitis B who visited the Second Department of Hepatology at Beijing Ditan Hospital, Capital Medical University, from November 21, 2025, to May 31, 2026. The subjects were grouped according to their drinking status into a non - drinking group, a drinking group, and a group that progressed to alcoholic hepatitis. The inclusion criteria are as follows: (1) Age between 30 and 75 years old (inclusive of 30 but exclusive of 75); (2) Subjects diagnosed with chronic hepatitis B; (3) Signed the informed consent form and were willing to follow the sampling and evaluation procedures of this study. The exclusion criteria include: (1) Patients with liver cirrhosis; (2) Pregnant and lactating women; (3) Subjects with a history of cancer in the past or at the time of screening; (4) A history of severe acute infectious diseases within 14 days before screening (such as severe and critical COVID - 19 infection, sepsis, etc.); (5) Use of the following drugs within 14 days before screening: intravenous/oral use of glucocorticoids; intravenous/oral use of azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide; (6) Subjects who had undergone organ transplantation, bone marrow transplantation, stem - cell transplantation before screening or had received blood transfusion within 30 days before screening; (7) Other situations judged by the researcher as unsuitable for participation in this study.

Considering the practical feasibility of the study and the calculation of the sample size, a sufficient number of samples need to be collected clinically to observe whether there are statistically significant differences. 25 cases were set in the non - drinking group and 50 cases in the drinking group. This sample size has 80% statistical power at a significance level of 0.05, which can detect moderately large differences, that is, we consider there are biologically meaningful differences. In addition, 10 cases of patients who progressed to alcoholic hepatitis were additionally collected, which was only for exploration and not based on precise formula calculations. Substituting the sample sizes of 25 non - drinking and 50 drinking cases, Cohen's d = 0.69, that is, the difference between the two groups is about 0.69 standard deviations. Under a two - sided test with α = 0.05, 80% statistical power can be achieved. Considering clinical practice and the enrollment path, there may be a certain dropout rate, estimated to be about 35%. Therefore, the actual number of blood samples to be collected is estimated to be about 130 cases.

Grouping description: (1) Non - drinking group: Drinking less than 2 times a year, with no limit on the amount of alcohol per time; (2) Drinking group: An average of at least 50g of alcohol per day. After the subjects pass the preliminary inclusion and exclusion review, pre - enrollment sampling is carried out. After collecting the imaging and blood test report information, it is confirmed whether the subject meets the enrollment and disease classification information, and the information collection and entry are completed.

Blood sample collection: Use disposable free DNA storage tubes to collect 2 tubes of whole - blood samples, 8 - 10 mL per tube. After collecting the whole - blood samples, number, label, and register them, and then transport the samples as required below. The collector disinfects the puncture site with iodine. Use a disposable free DNA storage tube to collect whole blood until there is no negative pressure (the volume of whole blood is 8 - 10 mL), gently invert and mix about 10 times. Collect 2 tubes of whole blood using a disposable free DNA storage tube as described above. Transport at room temperature (6 - 37°C). In case of extreme weather, remote areas, or other force majeure, professional cold chain transportation can be selected. After the collected blood samples arrive at the third - party testing laboratory (Shanghai Xiaohe Medical Laboratory Co., Ltd.), the plasma will be centrifuged and separated, and cfDNA will be extracted. After a series of experimental treatments such as methylation conversion, methylation DNA library construction, and hybridization capture, the NGS platform is used to detect the methylation level of cfDNA.

The complete statistical analysis includes statistics on inclusion and exclusion during screening, statistics on exclusions, and analysis of the main evaluation indicators. The main indicators to be described include the differential methylation profiles of cfDNA among groups with different drinking levels. Data analysis is performed using SPSS (v29) software for corresponding calculations. All statistical tests in this study use two - sided tests, and a p - value less than or equal to 0.05 will be considered statistically significant. All confidence intervals are estimated using 95% two - sided results.

The study consists of two phases, including the subject screening phase and the sampling phase. Screening phase: Enroll patients clinically diagnosed with chronic hepatitis B who meet the inclusion criteria as evaluated by the researcher, complete the informed consent for the clinical study, and sign the informed consent form. During the screening phase, basic information of the subjects, such as past medical history, medication, drinking, and demographic information, needs to be collected. Sampling phase: After pre - enrollment, 2 tubes of peripheral blood (about 8 mL per tube, a total of about 16 mL) are collected from the subjects for laboratory testing, and basic information such as the subjects' drinking habits and family history is collected. For all subjects, the blood and imaging test results from 6 months before pre - enrollment or 1 month after enrollment will also be collected, including indicators of chronic hepatitis B infection, liver function indicators, liver fibrosis indicators, and liver imaging examination data. If there are multiple test results, only the most recent test result before enrollment needs to be collected.

The study samples are fresh blood samples collected from subjects after signing the informed consent. The clinical information mainly comes from the HIS system. A case information collection form has been designed to collect the results of blood, imaging, and other indicators related to the subjects' chronic hepatitis B examinations.

03

Conditions studied

  • CHB

Browse trials for

Keywords

  • Chronic hepatitis B
  • DNA methylation
  • Drinking state
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study subjects were all inpatients and outpatients with chronic hepatitis B who visited the Second Department of Hepatology at Beijing Ditan Hospital, Capital Medical University, from November 21, 2025, to May 31, 2026. The subjects were grouped according to their drinking status into a non - drinking group, a drinking group, and a group that progressed to alcoholic hepatitis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 30 and 75 years old (inclusive of 30 but exclusive of 75)
  • Diagnosis of chronic
  • Signed form and willingness to comply with study sampling and evaluation procedures

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of liver cirrhosis
  • Pregnant or lactating women
  • Personal history of , either prior to or at screening
  • History of severe acute infectious diseases within 14 days before screening (e.g., severe or critical COVID-19 infection, sepsis)
  • Use of the following medications within 14 days before screening: intravenous/oral , intravenous/oral azacitidine, decitabine, procainamide, hydralazine, arsenic trioxide
  • Prior organ, bone marrow or stem cell transplantation, or blood transfusion within 30 days before screening
  • Any other condition deemed inappropriate for study participation by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
99 participants (actual)
Patient registry
No

Groups and cohorts

  • Non-drinking group

    Drink less than twice a year, with no limit on the amount of alcohol consumed each time.

  • Alcohol consumption group

    An average of at least 50 g per day.

  • Alcoholic hepatitis group
06

What researchers measure

Primary outcomes

  1. cfDNA methylation

    Plasma cell-free DNA methylation profile

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100015, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in May 2026, 6 months.

Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 18, 2026
StartActual
Nov 21, 2025
Primary completionActual
May 31, 2026
CompletionActual
May 31, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945392
Lead sponsor
Beijing Municipal Administration of Hospitals
Responsible party
Minghui Li (Head of Department, Beijing Municipal Administration of Hospitals) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 21, 2025
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update
Nov 18, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion